Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Bioavailability of Ipatasertib in Healthy Men
NCT02390492Phase 1Completed
- Sponsor
- Genentech
- Start
- Mar 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipatasertib in solid tumor, breast cancer and prostate cancer (PCa), sponsored by Genentech. Primary endpoints: Apparent terminal elimination half-life at 2 weeks, Apparent total clearance at 2 weeks and 9 more. Started Mar 2015; status: completed.
02
Drugs
ipatasertib
03
Conditions
solid tumorbreast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT02390492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390492.